VB15010

Primary objectives: To evaluate the safety and tolerability of VB15010 in subjects with advanced solid tumors; To determine the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) of VB15010 monotherapy; To determine the dosing regimen of VB15010 monotherapy. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of VB15010 in subjects with advanced solid tumors; To evaluate the preliminary efficacy of VB15010 in the treatment of subjects with advanced solid tumors. Exploratory objectives (Phase I): To explore the correlation between PARylation and/or HRR gene mutations (including but not limited to BRCA1/2, PALB2, RAD51C/D, etc.) and efficacy indicators.